80 FR 79595 - National Institute on Aging; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 245 (December 22, 2015)

Page Range		79595-79595
FR Document		2015-32036

Federal Register, Volume 80 Issue 245 (Tuesday, December 22, 2015)

[Federal Register Volume 80, Number 245 (Tuesday, December 22, 2015)]
[Notices]
[Page 79595]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-32036]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Aging Initial Review 
Group; Clinical Aging Review Committee.
    Date: February 4-5, 2016.
    Time: 2:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott and Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Alicja L. Markowska, Ph.D., DSC, National 
Institute on Aging, National Institutes of Health, Gateway Building 
2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-496-9666 
[email protected].

    Name of Committee: National Institute on Aging Initial Review 
Group; Biological Aging Review Committee.
    Date: February 4-5, 2016.
    Time: 2:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Bethesda North Marriott and Conference Center, 5701 
Marinelli Road, Bethesda, MD 20852.
    Contact Person: Bita Nakhai, Ph.D., Scientific Review Branch, 
National Institute on Aging, Gateway Bldg., 2C212, 7201 Wisconsin 
Avenue, Bethesda, MD 20814, 301-402-7701, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging 
Research, National Institutes of Health, HHS)

    Dated: December 16, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-32036 Filed 12-21-15; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 245 / Tuesday, December 22, 2015 / Notices 79595

ACTION: Notice. PCT application PCT/US2014/021514, amended (5 U.S.C. App.), notice is
filed March 7, 2014 entitled ‘‘Potent and hereby given of the following meetings.
SUMMARY: This is a notice, in accordance Selective Analogues of: Monamine The meetings will be closed to the
with 35 U.S.C. 209 and 37 CFR 404, that Transporters; Methods of Making; and public in accordance with the
the National Institute of Drug Abuse, Uses Thereof’’ [HHS Ref. No. E–073– provisions set forth in sections
National Institutes of Health, 2013/0–PCT–02]; 552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
Department of Health and Human U.S. application 14/772,486, filed as amended. The grant applications and
Services is contemplating the grant of an September 3, 2015 entitled ‘‘Potent and the discussions could disclose
exclusive start-up option license to Selective Analogues of Monamine confidential trade secrets or commercial
practice the inventions embodied in the Transporters; Methods of Making; and property such as patentable material,
following Patent Applications and all Uses Thereof’’ [HHS Ref. No. E–073– and personal information concerning
related continuing and foreign patents/ 2013/0–US–06]; individuals associated with the grant
patent applications for the technology applications, the disclosure of which
EPO application 14714043.8, filed
family to EncepHeal Therapeutics, Inc., would constitute a clearly unwarranted
September 1, 2015 entitled ‘‘Potent and
located in Winston-Salem, North invasion of personal privacy.
Selective Analogues of Monamine
Carolina.
Transporters; Methods of Making; and Name of Committee: National Institute on
DATES: Only written comments and/or Uses Thereof’’ [HHS Ref. No. E–073– Aging Initial Review Group; Clinical Aging
applications for a license which are 2013/0–EP–05]; Review Committee.
received by the NCI Technology Australian application 2014225550, Date: February 4–5, 2016.
Transfer Center on or before January 6, Time: 2:00 p.m. to 3:00 p.m.
filed September 8, 2015 entitled ‘‘Potent Agenda: To review and evaluate grant
2016 will be considered. and Selective Analogues of Monamine applications.
ADDRESSES: Requests for copies of the Transporters; Methods of Making; and Place: Bethesda North Marriott and
patent application, inquiries, comments, Uses Thereof’’ [HHS Ref. No. E–073– Conference Center, 5701 Marinelli Road,
and other materials relating to the 2013/0–AU–03]; Bethesda, MD 20852.
contemplated exclusive license should Canadian application 2903746, filed Contact Person: Alicja L. Markowska,
be directed to Martha Lubet, Ph.D., Ph.D., DSC, National Institute on Aging,
September 2, 2015 entitled ‘‘Potent and
Technology Transfer Specialist, NCI National Institutes of Health, Gateway
Selective Analogues of Monamine Building 2C212, 7201 Wisconsin Avenue,
TTC, 9609 Medical Center Drive, Room Transporters; Methods of Making; and Bethesda, MD 20892, 301–496–9666
IE350, and Rockville, MD 20850. Uses Thereof’’ [HHS Ref. No. E–073– markowsa@nia.nih.gov.
Telephone: (240) 276–5508. Facsimile: 2013/0–CA–04]; Name of Committee: National Institute on
(240) 276–5505. Email: lubetm@ The patent rights to these inventions Aging Initial Review Group; Biological Aging
mail.nih.gov. have been assigned to and/or Review Committee.
SUPPLEMENTARY INFORMATION: This exclusively licensed to the Government Date: February 4–5, 2016.
of the United States of America. Time: 2:00 p.m. to 3:00 p.m.
invention concerns analogues of Agenda: To review and evaluate grant
modafinil and methods of using the The prospective exclusive start-up applications.
analogues for the treatment of substance option licensed territory may be Place: Bethesda North Marriott and
use disorders and sleep disorders. worldwide and the field of use may be Conference Center, 5701 Marinelli Road,
The prospective exclusive start-up limited to: (a) Treatment of substance Bethesda, MD 20852.
option license will be royalty bearing use disorders and/or (b) treatment of Contact Person: Bita Nakhai, Ph.D.,
and will comply with the terms and sleep disorders. Scientific Review Branch, National Institute
conditions of 35 U.S.C. 209 and 37 CFR on Aging, Gateway Bldg., 2C212, 7201
Upon the expiration or termination of
Wisconsin Avenue, Bethesda, MD 20814,
part 404. The prospective exclusive the exclusive start-up option license, 301–402–7701, nakhaib@nia.nih.gov.
start-up option may be granted unless EncepHeal Therapeutics, Inc. will have (Catalogue of Federal Domestic Assistance
within fifteen (15) days from the date of the exclusive right to execute a start-up Program Nos. 93.866, Aging Research,
this published notice, the NCI receives exclusive commercialization license National Institutes of Health, HHS)
written evidence and argument that which will supersede and replace the
establishes that the grant of the license Dated: December 16, 2015.
exclusive start-up option license with
would not be consistent with the no greater field of use and territory than Melanie J. Gray,
requirements of 35 U.S.C. 209 and 37 granted in the exclusive start-up option Program Analyst, Office of Federal Advisory
CFR part 404. Committee Policy.
license.
Complete applications for a license in [FR Doc. 2015–32036 Filed 12–21–15; 8:45 am]
Dated: December 17, 2015.
the field of use filed in response to this BILLING CODE 4140–01–P
Richard U. Rodriguez,
notice will be treated as objections to
the grant of the contemplated exclusive Associate Director, Technology Transfer
Center, National Cancer Institute. DEPARTMENT OF HEALTH AND
start-up option license. Comments and
objections submitted to this notice will [FR Doc. 2015–32141 Filed 12–21–15; 8:45 am] HUMAN SERVICES
not be made available for public BILLING CODE 4140–01–P

inspection and, to the extent permitted National Institutes of Health
by law, will not be released under the Eunice Kennedy Shriver National
Freedom of Information Act, 5 U.S.C. DEPARTMENT OF HEALTH AND
HUMAN SERVICES Institute of Child Health & Human
mstockstill on DSK4VPTVN1PROD with NOTICES

552. Development; Notice of Meeting
Intellectual Property:
National Institutes of Health
U.S. provisional application 61/ Pursuant to section 10(d) of the
774,878, filed March 8, 2013 entitled National Institute on Aging; Notice of Federal Advisory Committee Act, as
‘‘Potent and Selective Inhibitors of Closed Meetings amended (5 U.S.C. App.), notice is
Monamine Transporters; Methods of hereby given of a meeting of the
Making; and Uses Thereof’’ [HHS Ref. Pursuant to section 10(d) of the National Advisory Child Health and
No. E–073–2013/0–US–01]; Federal Advisory Committee Act, as Human Development Council.

VerDate Sep<11>2014 17:21 Dec 21, 2015 Jkt 238001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\22DEN1.SGM 22DEN1

Document Created: 2015-12-22 02:31:56
Document Modified: 2015-12-22 02:31:56

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		February 4-5, 2016.
FR Citation		80 FR 79595

80 FR 79595 - National Institute on Aging; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 245 (December 22, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health